Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
An article from
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
Published May 21, 2026
The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
Michael M. Santiago via Getty Images
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
BlackRock-backed fintech is going public in a bid to bring more credibility and capital to one of crypto’s hottest corners:…
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in…
The SPAC King's newest, dubbed "American Exceptionalism," went public with $345 million. But Chamath doesn't want people to buy…
iRocket is aiming to hit the public markets but the SPAC vehicle doesn't have much cash left.
Exclusive: Another I&I biotech, Gerhart-led cAMPfield, draws top-tier investors in $180M Series A
Aura Biosciences Inc (AURA) Gets a Buy from LifeSci Capital
Cerebras just had the biggest US tech IPO since Snowflake. SpaceX, OpenAI, and Anthropic are next.
Cerebras' blockbuster IPO boosts hype for SpaceX and OpenAI, but crowds out smaller players
Parabilis reveals IPO plans the day after Regeneron deal as listings heat up
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
Cork-based Atlantia Clinical Trials to enter medtech market with €1.5m investment
A new ranking of pharma companies by R&D performance
Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech
Investment giants join forces to form largest healthcare firm on the globe - Pharmaceutical Technology
